Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment Quiver Quantitative, Inc. - Mon Dec 16, 4:52PM CST

Real-world evidence study shows ANX005 improves muscle strength and functional outcomes in Guillain-Barré Syndrome compared to current treatments.Quiver AI SummaryAnnexon, Inc. announced positive topline...

ANNX : 5.23 (+0.19%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Dec 16, 3:05PM CST

ANNX : 5.23 (+0.19%)
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS) GlobeNewswire - Mon Dec 16, 6:30AM CST

ANNX : 5.23 (+0.19%)
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting GlobeNewswire - Thu Dec 5, 7:00AM CST

ANNX : 5.23 (+0.19%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Nov 15, 3:59PM CST

ANNX : 5.23 (+0.19%)
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones GlobeNewswire - Thu Nov 14, 7:00AM CST

ANNX : 5.23 (+0.19%)
Annexon Biosciences to Present at the Jefferies London Healthcare Conference GlobeNewswire - Wed Nov 13, 3:05PM CST

ANNX : 5.23 (+0.19%)
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting GlobeNewswire - Mon Oct 21, 7:00PM CDT

ANNX : 5.23 (+0.19%)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Oct 16, 7:00AM CDT

ANNX : 5.23 (+0.19%)
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting GlobeNewswire - Tue Oct 15, 7:00AM CDT

ANNX : 5.23 (+0.19%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot